Researcher want to compare and evaluate the effect of sugammadex on postoperative recovery,
with a focus on the occurrence of postoperative urinary dysfunction, in patients who have
undergone regular abdominal surgery within a year of being infected with and treated for
COVID-19.
Post COVID-19 condition is a new and poorly understood clinical syndrome with potentially
significant and life-altering consequences. Recent studies suggest that patients who have
recovered from COVID-19 may experience autonomic dysfunction and be at risk for autonomic
dysregulation/syndrome. In most patients undergoing general anesthesia, neuromuscular
blockers are used, and their residual effects delay the recovery of autonomic function after
surgery, leading to problems such as worsening bladder and bowel function. Therefore,
reversal agents are used to aid in postoperative muscle recovery, with sugammadex and
neostigmine being commonly used in clinical practice. While sugammadex is generally expected
to result in faster postoperative recovery, limited reports exist on its effectiveness in
patients who have recovered from COVID-19. This study aims to verify whether sugammadex is
more effective than neostigmine in aiding the recovery of bowel and pulmonary function after
surgery in patients who have recovered from COVID-19.